Nuclear factor-kappa B inhibitors; a patent review (2006 – 2010)

Author： Kwak Jae-Hwan   Jung Jae-Kyung   Lee Heesoon  

Publisher： Informa Healthcare

ISSN： 1354-3776

Source： Expert Opinion on Therapeutic Patents, Vol.21, Iss.12, 2011-12, pp. : 1897-1910

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Direct Covalent Modification as a Strategy to Inhibit Nuclear Factor-Kappa B

By  

Current Medicinal Chemistry, Vol. 16, Iss. 32, 2009-11 ,pp. : 4261-4273

Bentham Science Publishers

Access to resources Recommend Favorite

Enoyl acyl carrier protein reductase inhibitors: a patent review (2006 –– 2010)

By Lu Xiaoyun   Huang Kun   You Qidong  

Expert Opinion on Therapeutic Patents, Vol. 21, Iss. 7, 2011-07 ,pp. : 1007-1022

Informa Healthcare

Access to resources Recommend Favorite

Aminopeptidase N (EC 3.4.11.2) inhibitors (2006 –– 2010): a patent review

By Su Li   Fang Hao   Xu Wenfang  

Expert Opinion on Therapeutic Patents, Vol. 21, Iss. 8, 2011-08 ,pp. : 1241-1265

Informa Healthcare

Access to resources Recommend Favorite

Novel Dual Inhibitors of Nuclear Factor-Kappa B (NF-κ B) and Cyclooxygenase- 2 (COX-2): Synthesis, In Vitro Anticancer Activity and Stability Studies of Lantadene–Non Steroidal Anti-inflammatory Drug (NSAID) Conjugates

By  

Current Topics in Medicinal Chemistry, Vol. 14, Iss. 8, 2014-04 ,pp. : 991-1004

Bentham Science Publishers

Access to resources Recommend Favorite

Oxymatrine inhibits lipopolysaccharide-induced inflammation by down-regulating Toll-like receptor 4/nuclear factor-kappa B in macrophages

By Zhang Yu   Yan Ruhong   Hu Yae  

Canadian Journal of Physiology and Pharmacology, Vol. 93, Iss. 4, 2015-01 ,pp. : 253-260

NRC Research Press

Access to resources Recommend Favorite